• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,386.69 -941.50
( -1.22%)
Global Indices
Nasdaq
49,619.91 1.93
(0.00%)
Dow Jones
7,417.79 59.68
(0.81%)
Hang Seng
62,457.26 -256.39
(-0.41%)
Nikkei 225
10,228.01 -48.94
(-0.48%)
Forex
USD-INR
94.38 -0.30
(-0.31%)
EUR-INR
110.93 -0.26
(-0.23%)
GBP-INR
128.32 -0.39
(-0.30%)
JPY-INR
0.60 0.00
(-0.28%)

EQUITY - MARKET SCREENER

Lupin Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
500257
INE326A01037
659.0710314
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
LUPIN
18.03
108721.36
EPS(TTM)
Face Value()
Div & Yield %
131.92
2
0.76
 

Greenlam Industries announces acquisition of balance 33% in its Indonesian subsidiary
Apr 06,2026

Greenlam Asia Pacific, a wholly owned subsidiary of Greenlam Industries in Singapore (Singapore subsidiary) and Greenlam Industries SDN. BHD., a wholly owned subsidiary of Singapore subsidiary in Malaysia (Malaysia subsidiary), have jointly acquired the entire 33% local shareholding of PT. Greenlam Indo Pacific, a subsidiary of Singapore subsidiary in Indonesia (Indonesia subsidiary/ target entity ).

The Singapore subsidiary earlier held 67% shareholding in the target entity. Pursuant to the above acquisition, the collective shareholding of Singapore subsidiary and Malaysia subsidiary now stands at 100%. Consequently, the target entity has become a wholly owned (step-down) subsidiary of Greenlam Industries.